- Open Access
Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials
Journal of Hematology & Oncology volume 15, Article number: 69 (2022)
International clinical practice guidelines have progressively endorsed direct oral anticoagulants (DOACs) as an alternative to low-molecular-weight heparins (LMWHs) monotherapy for the initial and long-term treatment of cancer-associated thrombosis (CAT). Several new randomized controlled trials (RCTs) have recently reported additional results on the safety and efficacy of DOACs in this setting. We performed an updated meta-analysis of all publicly available data from RCTs comparing DOACs with LMWHs for the treatment of CAT. Six RCTs enrolling 3690 patients with CAT were included. Compared with LMWHs, DOACs significantly decreased the risk of CAT recurrence (RR, 0.67; 95%CI, 0.52–0.85), with a non-significant increase in the risk of major bleeding (RR, 1.17; 95%CI, 0.82–1.67), a significant increase in the risk of clinically relevant nonmajor bleeding (RR 1.66; 95%CI, 1.31–2.09) and no difference in all-cause mortality rates. These results increase the level of certainty of available evidence supporting the use of DOACs as an effective and safe option for the treatment of CAT in selected cancer patients.
To the editor
International evidence-based clinical practice guidelines (CPGs), which provide recommendations for the best available care options and guide clinical decision-making, have progressively endorsed direct oral anticoagulants (DOACs) as an alternative to monotherapy with low-molecular-weight heparins (LMWHs) for the initial and long-term treatment of cancer-associated thrombosis (CAT) [1,2,3,4]. Several new randomized controlled trials (RCTs) have recently reported additional results on the safety and efficacy of DOACs in this setting. Here, we perform an updated study-level meta-analysis of all publicly available results from RCTs comparing DOACs with LMWHs for the treatment of CAT. The literature search and selection process identified 6 RCTs meeting the inclusion criteria [5,6,7,8,9,10], which were further included in the pooled-analyses (Additional File 1). Together, these trials enrolled a total of 3690 patients with acute CAT (1850 randomized to the DOACs arms and 1840 randomized to the LMWHs arms). Study characteristics are depicted in Table 1. All studies were open label, used a blinded central outcome adjudication design and were estimated to have low risk for performance and detection bias (Additional File 1). During a 3–6 months follow-up under anticoagulant treatment (intention-to-treat population), recurrent venous thromboembolism (VTE) occurred in 99 of 1850 patients receiving DOACs vs. 152 of 1840 patients receiving LMWHs. The risk of recurrent VTE was significantly lower with DOACs compared to LMWHs (RR, 0.67; 95%CI, 0.52–0.85; p = 0.001; I2 = 0%; Fig. 1). With a rate of VTE recurrence of 8.3% in patients receiving LMWHs, the absolute risk reduction with DOACs was 2.7% (95%CI, –4 to –1.2; high certainty of evidence). Major bleeding occurred in 80 of 1850 patients receiving DOACs vs. 68 of 1840 patients receiving LMWHs. Although the risk of major bleeding was numerically higher with DOACs, this difference did not reach statistical significance (RR, 1.17, 95%CI, 0.82–1.67; p = 0.39; I2 = 12%; Fig. 1). With a risk of major bleeding of 3.7% in the LMWHs group, the absolute risk increase with DOACs was 0.6% (95%CI, –0.7 to 2.5; high certainty of evidence). Clinically relevant nonmajor bleeding (CRNMB) occurred more frequently in patients receiving DOACs compared to those receiving LMWHs (RR, 1.66, 95%CI, 1.31–2.09; p < 0.0001; I2 = 0%, Fig. 1). With a risk of CRNMB of 5.7% in patients receiving LMWHs, the absolute risk increase with DOACs was 3.8% (95% CI, 1.8–6.2). Finally, the rate of all-cause mortality did not differ between the 2 groups (23.3% in the DOACs arms vs. 23.5% in the LMWHs arms; RR, 1.02, 95%CI, 0.89–1.16; p = 0.80; I2 = 13%, Fig. 1). Per Grading of Recommendations Assessment, Development and Evaluation criteria, the quality of evidence was judged to be high for all outcomes.
By pooling the results from 6 high quality RCTs, the present study provides more precise estimates of the anticipated treatment effects. Our findings indicate that in cancer patients, DOACs confer a slight reduction in the risk of recurrent VTE. The proportion of patients discontinuing treatment was lower in those randomized to receive a DOAC compared to those randomized to receive a LMWH, which may explain, in part, the superior efficacy of DOACs. The exclusion criteria used in most RCTs (ECOG Performance Status > 2, brain tumors, platelet count < 50–75 G.L−1, Cockroft Clairance < 30 ml.min−1) may have limited the generalizability of the findings. Importantly, bleeding was more common in patients with gastrointestinal (GI) malignancies receiving edoxaban or rivaroxaban compared with LMWHs [5, 6], while apixaban was not associated with an increased risk of bleeding in these patients [7, 8].
In conclusion, there is growing evidence supporting DOACs as an effective and safe treatment option for VTE in selected cancer patients. Results from the present study increase the level of confidence on available evidence supporting the safety and efficacy of DOACs for the treatment of CAT. LMWHs remain the preferred treatment option in cancer patients at high risk of bleeding, such as GI cancer patients, those who require frequent dose adjustments with chemotherapy-induced thrombocytopenia, those who receive ongoing anticancer therapies with potential drug-drug interactions, as well as those with brain metastases. Dedicated tools, such as the ITAC-CME multi-language web-based mobile application downloadable for free at www.itaccme.com will help to improve the care and quality of life of cancer patients and to further decrease the burden of CAT.
Availability of data and materials
The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.
Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss S, Brilhante D, Monreal M, Bounameaux H, Pabinger I, Douketis J, International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20:e566–81.
Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020;38:496–520.
Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, Leavitt AD, Lee AYY, Macbeth F, Morgan RL, Noble S, Sexton EA, Stenehjem D, Wiercioch W, Kahale LA, Alonso-Coello P. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5:927–74.
NCCN Guideline on Cancer-Associated Venous Thromboembolic Disease. Version 1. 2022. Available at https://www.nccn.org/ professionals/physician_gls/pdf/vte.pdf. Accessed March, 2022.
Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang T-F, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR, Hokusai VTE Cancer Investigators. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2018; 378: 615–24
Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017–23.
McBane RD, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020;18:411–21.
Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M, Caravaggio Investigators. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020;382:1599–607
Planquette B, Bertoletti L, Charles-Nelson A, Laporte S, Grange C, Mahé I, Pernod G, Elias A, Couturaud F, Falvo N, Sevestre MA, Ray V, Burnod A, Brebion N, Roy P-M, Timar-David M, Aquilanti S, Constans J, Bura-Riviere A, Brisot D, et al. Rivaroxaban versus dalteparin in cancer-associated thromboembolism: a randomized trial. Chest. 2021;S0012-3692(21):04079–84.
Schrag D, Uno H, Rosovsky RPG, Rutherford C, Sanfilippo KM, Villano JL, Drescher MR, Jayaram NH, Holmes CE, Feldman LE, Zattra O, Cronin C, Basch EM, Weiss A, Connors JM. The comparative effectiveness of direct oral anti-coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: The CANVAS pragmatic randomized trial. JCO Wolters Kluwer. 2021;39:12020.
The current study was supported by the International Initiative on Thrombosis and Cancer-Continuous Medical Education (ITAC-CME, www.itaccme.com) without funding from industry.
Ethics approval and consent to participate
The study was conducted according to the principles of the Declaration of Helsinki and registered on PROSPERO (CRD42021266069).
Consent for publication
C.F. reported receiving honoraria for participating as a speaker at satellite symposia organized by Bayer, Bristol Myers Squibb, and LEO Pharma; D.S. reported receiving compensation for speaking at a Pfizer satellite symposium in 2019, receiving services for editorial work for JAMA, and research funding from the AACR for project GENIE; J.M.C. reported receiving personal fees from Bristol Meyers Squibb, Pfizer, Abbott, Alnylam, Takeda, Roche, and Sanofi. D.F. and P.H.C have nothing to disclose.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Frere, C., Farge, D., Schrag, D. et al. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol 15, 69 (2022). https://doi.org/10.1186/s13045-022-01289-1
- Venous thromboembolism
- Direct oral anticoagulant
- Low-molecular-weight heparin